Valuation Abbott Laboratories Swiss Exchange
Stocks
ABT
US0028241000
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 85.00 CHF | -3.41% |
|
+0.59% | -14.14% |
| 01/08 | Amgen discloses data breach involving patient health information | RE |
| 31/07 | Dexcom raises annual revenue forecast on strong demand for glucose monitors | RE |
Company Valuation: Abbott Laboratories
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,41,365 | 1,91,427 | 1,91,088 | 1,96,184 | 2,17,859 | 1,82,902 | - | - |
| Change | - | -20.69% | -0.18% | 2.67% | 11.05% | -16.05% | - | - |
| Enterprise Value (EV) 1 | 2,49,166 | 1,98,318 | 1,98,871 | 2,02,693 | 2,22,266 | 2,07,067 | 2,04,318 | 2,00,517 |
| Change | - | -20.41% | 0.28% | 1.92% | 9.66% | -6.84% | -1.33% | -1.86% |
| P/E | 35.7x | 28.1x | 33.8x | 14.8x | 33.7x | 30.3x | 23.4x | 21x |
| PBR | 6.93x | 5.2x | 4.94x | 4.11x | 4.18x | 3.8x | 3.64x | 3.43x |
| PEG | - | -36.9x | -2x | 0x | -0.7x | -4.95x | 0.8x | 1.8x |
| Capitalization / Revenue | 5.6x | 4.39x | 4.76x | 4.68x | 4.91x | 3.64x | 3.35x | 3.13x |
| EV / Revenue | 5.78x | 4.54x | 4.96x | 4.83x | 5.01x | 4.12x | 3.74x | 3.43x |
| EV / EBITDA | 19.4x | 15.9x | 19.5x | 19.1x | 18.9x | 16x | 14.1x | 12.7x |
| EV / EBIT | 22x | 17.7x | 22.3x | 21.8x | 21.6x | 17.7x | 15.7x | 14x |
| EV / FCF | 28.8x | 25.4x | 39.3x | 31.9x | 30.1x | 26.1x | 21.8x | 19.6x |
| FCF Yield | 3.47% | 3.94% | 2.54% | 3.13% | 3.33% | 3.83% | 4.58% | 5.09% |
| Dividend per Share 2 | 1.82 | 1.92 | 2.08 | 2.24 | 2.4 | 2.577 | 2.739 | 2.854 |
| Rate of return | 1.29% | 1.75% | 1.89% | 1.98% | 1.92% | 2.44% | 2.59% | 2.7% |
| EPS 2 | 3.94 | 3.91 | 3.26 | 7.64 | 3.72 | 3.492 | 4.522 | 5.038 |
| Distribution rate | 46.2% | 49.1% | 63.8% | 29.3% | 64.5% | 73.8% | 60.6% | 56.7% |
| Net sales 1 | 43,075 | 43,653 | 40,109 | 41,950 | 44,328 | 50,304 | 54,649 | 58,413 |
| EBITDA 1 | 12,815 | 12,485 | 10,188 | 10,635 | 11,735 | 12,951 | 14,445 | 15,797 |
| EBIT 1 | 11,324 | 11,231 | 8,911 | 9,295 | 10,301 | 11,718 | 13,019 | 14,321 |
| Net income 1 | 7,071 | 6,933 | 5,723 | 13,402 | 6,524 | 6,255 | 7,923 | 8,786 |
| Net Debt 1 | 7,801 | 6,891 | 7,783 | 6,509 | 4,407 | 24,166 | 21,416 | 17,615 |
| Reference price 2 | 140.74 | 109.79 | 110.07 | 113.11 | 125.29 | 105.70 | 105.70 | 105.70 |
| Nbr of stocks (in thousands) | 17,14,968 | 17,43,574 | 17,36,059 | 17,34,455 | 17,38,834 | 17,30,383 | - | - |
| Announcement Date | 26/01/22 | 25/01/23 | 24/01/24 | 22/01/25 | 22/01/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 19.35x | 3.38x | 11.9x | 3.48% | 11TCr | ||
| 17.32x | 0.19x | 12.22x | 0.76% | 6.06TCr | ||
| 30.21x | 7.51x | 18.82x | 1.35% | 5.18TCr | ||
| 36.06x | 3.22x | 10.97x | 2.37% | 4.56TCr | ||
| 37.66x | 1.37x | 12.1x | 0.21% | 3.32TCr | ||
| 33.77x | 5.98x | 18.8x | -.--% | 3.15TCr | ||
| 39.76x | 6.96x | 24.98x | 0.26% | 2.4TCr | ||
| 24.32x | 3.69x | 12.93x | 1.14% | 2.23TCr | ||
| 20.37x | 2.82x | 10.88x | 1.55% | 2.15TCr | ||
| Average | 28.76x | 3.90x | 14.85x | 1.24% | 4.44TCr | |
| Weighted average by Cap. | 26.57x | 3.65x | 14.09x | 1.69% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ABT Stock
- ABT Stock
- Valuation Abbott Laboratories
Select your edition
All financial news and data tailored to specific country editions
















